Cristina Rosell-Cardona , Emily G. Knox , Paula Sánchez-Díaz , Sarah-Jane Leigh , Emanuela Tirelli , Michael S. Goodson , Nancy Kelley-Loughnane , María R. Aburto , Sarah Kittel-Schneider , John F. Cryan , Gerard Clarke
{"title":"Microbial tryptophan metabolites modulate blood-brain and gut barriers in vitro","authors":"Cristina Rosell-Cardona , Emily G. Knox , Paula Sánchez-Díaz , Sarah-Jane Leigh , Emanuela Tirelli , Michael S. Goodson , Nancy Kelley-Loughnane , María R. Aburto , Sarah Kittel-Schneider , John F. Cryan , Gerard Clarke","doi":"10.1016/j.nsa.2025.106876","DOIUrl":null,"url":null,"abstract":"<div><div>The gut microbiota influences brain function via the gut-brain axis, but the underlying molecular processes remain unclear. Critical to this communication are barrier systems, such as the epithelial gut and the blood-brain barrier, which mediate the interface between circulating signals and gut-brain communication. Microbial metabolites are key mediators of the gut microbiota that can influence barrier integrity. In this study, we used well-established <em>in vitro</em> models of the blood-brain and gut barriers and exposed them to a wide range of physiologically relevant stress-associated microbial metabolites, including tryptophan-derived metabolites with and without lipopolysaccharide (LPS) as a disrupting insult. We demonstrated that indole, indole-3-acetate, indole-3-propionate and tryptamine can modulate both gut and brain barriers in a dose- and cell-type dependent manner. Our findings suggest that specific indole metabolites should be further evaluated as promising novel therapeutic interventions to regulate barrier integrity along the microbiota-gut-brain axis.</div></div>","PeriodicalId":100952,"journal":{"name":"Neuroscience Applied","volume":"5 ","pages":"Article 106876"},"PeriodicalIF":3.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroscience Applied","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772408525014681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The gut microbiota influences brain function via the gut-brain axis, but the underlying molecular processes remain unclear. Critical to this communication are barrier systems, such as the epithelial gut and the blood-brain barrier, which mediate the interface between circulating signals and gut-brain communication. Microbial metabolites are key mediators of the gut microbiota that can influence barrier integrity. In this study, we used well-established in vitro models of the blood-brain and gut barriers and exposed them to a wide range of physiologically relevant stress-associated microbial metabolites, including tryptophan-derived metabolites with and without lipopolysaccharide (LPS) as a disrupting insult. We demonstrated that indole, indole-3-acetate, indole-3-propionate and tryptamine can modulate both gut and brain barriers in a dose- and cell-type dependent manner. Our findings suggest that specific indole metabolites should be further evaluated as promising novel therapeutic interventions to regulate barrier integrity along the microbiota-gut-brain axis.